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rEsuMo
os objectivos deste estudo foram: (1) Determinar os níveis de metilação do promotor do MDR1 em tecido prostático 
com adenocarcinoma (cap), neoplasia intraepitelial prostática de alto grau (Hgpin), hiperplasia benigna (bpH) e teci-
do morfologicamente normal (mnp). (2) correlacionar os níveis de metilação com a imunoexpressão da gp-p.
os nossos resultados demonstram que a hipermetilação do MDR1 constitui um mecanismo eficaz de regulação da 
sua expressão. estudos futuros permitirão avaliar o impacto destes resultados na terapêutica do cancro da próstata.
PALAVRAS-ChAVE: cancro da próstata ; MDR1; gp-p; metilação do promotor; epigénetica.
abstraCt
our aims were: (1) to determine the MDR1 methylation levels in tissue of prostate cancer (pca), high grade prosta-
tic intraepithelial neoplasia (Hgpin), benign prostatic hyperplasia (bpH) and morphologically normal prostate tissue 
(mnp); (2) to correlate the methylation levels of the MDR1 promoter with the immunoexpression of p-gp.
our results demonstrate that MDR1 hypermethylation constitutes an effective mechanism of p-gp expression regu-
lation. Future studies will be able to evaluate the impact of these results in the treatment of pca patients.
KEy-WORDS: prostate cancer; MDR1; p-gp; promoter methylation; epigenetics.
126 1. introduction
prostate carcinoma (pca) is the sixth most frequently diagnosed cancer in the world and the second 
leading cause of men death in europe and usA (lara et al., 2004; perry et al., 2006). the diagnosis of pca 
in early stages is crucial for a curative treatment, since in advanced disease the resistance to androgen-
ablation therapy results in a high probability of death (perry et al., 2006). As current diagnostic metho-
dologies fail to detect or correctly predict the outcome of a large percentage of prostate carcinomas, 
the discovery of novel molecular markers with diagnostic and/or prognostic potential is of paramount 
importance for the clinical management of these patients. promising results using epigenetic markers 
have shown the importance of DnA hypermethylation of several genes in prostate cancer development, 
and the evaluation of methylation level of a small panel of deregulated genes (e.g.: GSTP1, APC, RARβ2 
and MDR1) should thus prove valuable in establishing a correct pca diagnosis and assess the prognosis 
of the patients (enokida et al., 2005; costa et al., 2007a).
the MDR1 gene (“multidrug resistance receptor 1”), mapped at 7q21, encodes for p-glycoprotein (p-gp), 
a membrane Atp-dependent efflux transporter composed of 1280 amino acids (Ambudkar et al., 2003; 
rao et al., 2005). in normal conditions, MDR1 is mainly expressed in gastrointestinal, liver and kidney 
epithelia, and capillary endothelial cells in brain, testis and ovary (Ambudkar et al., 2003). it is known 
that the p-gp protects the body from environmental toxins and xenobiotics, promoting its excretion 
in bile and urine (Ambudkar et al., 2003). Additionally, p-gp has an important pharmacokinetic role by 
interacting with several drugs, such as Vinca alkaloids, topoisomerase ii inhibitors and steroid hormones 
(Ambudkar et al., 2003). p-gp was originally discovered as the mediator of the multidrug resistance phe-
notype (mDr) of cell lines selected in vitro for resistance to several anticancer drugs (Kawai et al., 2002). 
subsequent studies revealed that p-gp is expressed in a tissue-specific manner and that in several ma-
lignancies p-gp overexpression is frequent and may constitute an adaptive response to chemotherapy 
(bhangal et al., 1999). in prostate carcinoma, however, p-gp expression seems to be lower than normal 
prostatic cells (bhangal et al., 1999; Kawai et al., 2002).
p-gp is an energy dependent Abc transporter (Atp-binding cassette transporter) whose function is to 
drive drugs out from cells. this molecule is formed by two homologue domains, each containing six 
trans-membrane domains (tm) where drug binding occurs, and two Atp-binding sites (Figure 1). they 
are separated by a flexible binding region, which promotes the communication between the Atp-bin-
ding sites. in this intrinsic biochemical process the Atp hydrolysis produces energy for drug transport. 









figure 1. Hypothetical 2-D model of human p-gp. Adapted from Ambudkar et al. (2003).
127DnA methylation and other epigenetic mechanisms, such as histone modifications, play an important 
role in regulation of gene expression by altering chromatin structure and hence affecting gene expres-
sion in a heritable manner without directly interfering with the genetic code (Kusaba et al., 1999; Herman 
et al., 2003, perry et al., 2006; esteller, 2007). methylation of promoter cpg islands results in transcriptional 
silencing through several mechanisms, as the attraction of proteins that interact with histone deacetyla-
ses and chromatin condensation preclude the binding of transcriptional factors to the promoter (perry et 
al., 2006). epigenetic alterations modulate gene expression and may modify the tumour phenotype. As a 
result, the bulk of methylation in a tumour may reflect its course (perry et al., 2006; Dobosy et al., 2007). in 
contrast with genetic alterations, cpg island hypermethylation occurs very frequently in pca (cho et al., 
2007). Hence, this alteration is widely accepted as an important carcinogenic mechanism of pca and has 
been suggested by several studies as a tumour marker and prognostic factor (cho et al., 2007). Different 
surveys have reported a high frequency of MDR1 promoter hypermethylation in pca (enokida et al., 2004; 
enokida et al., 2005; costa et al., 2007a). Although recent investigations suggest that this epigenetic altera-
tion regulates gene expression, the experimental data to sustain this hypothesis is scarce.
2. oBJectives
our aims were: (1) to determine MDR1 promoter methylation levels in pca, high grade prostatic intra-
epithelial neoplasia (Hgpin), benign prostatic hyperplasia and morphologically normal prostate tissue 
(mnp); (2) to correlate the methylation levels with the immunoexpression of p-gp.
3. metHods/eXPerimental design
one hundred and one men with clinically localized pca, consecutively diagnosed and primarily submit-
ted to radical prostatectomy in i.p.o.F.g – porto were included in this study [stage t1c and t2, according 
to tnm system (Hermanek et al., 1997)]. prostatic intraepithelial neoplasia (pin) lesions were identified 
in 39 cases and also collected for further analysis. bpH specimens were collected from 28 patients sub-
mitted to transurethral resection and selected for sample controls. All specimens were frozen at -80ºc 
and then cut with a cryostat for microscopic evaluation and selection of potential areas for analysis. cut 
sections were trimmed to maximize target cell content (>70%) and then DnA extraction was performed 
using phenol-chloroform. From each specimen, parallel fragments were collected, formalin treated and 
paraffin-embedded for histopathological examination. gleason score (gleason et al., 1974) and patho-
logical staging (Hermanek et al., 1997) were evaluated by an expert pathologist. relevant clinical data, 
including prostate-specific antigen (psA), was collected for each patient (Kort et al., 2006). these studies 
were approved by the ethics commission of i.p.o.F.g – porto.
3.1. DNa ExtraCtIoN
After overnight digestion in lysis buffer and proteinase K at 55ºc, DnA was extracted from all samples 
with phenol-chloroform. the aqueous phase was transferred to eppendorf tubes and DnA was precipi-
tated at -20ºc overnight by addition of absolute ethanol and 7,5m ammonium acetate. DnA pellets were 
washed twice with 70% ethanol and finally eluted in distilled water (ddH
2
o).
128 3.2. soDIuM bIsulpHItE CoNvErsIoN
sodium bisulphite reaction allows for DnA methylation analysis by converting non-methylated cytosine 
residues to uracil residues, while methylated cytosines residues remain without any modification (clark 
et al., 1994). target DnA was further amplified in quantitative methylation-specific pcr, where all uracils 
and thymines are amplified as thymines, whereas methylated cytosines appear as cytosines (olek et al., 
1996). briefly, we start by quantifying DnA concentration in all samples using a nanoDrop spectrophoto-
meter (nanoDrop, usA). As bisulphite conversion only occurs when the template is in a single-stranded 
conformation, DnA was denatured by incubation with 3m naoH for 20 minutes at 50ºc. the DnA con-
version mixture was prepared using 9,5g of sodium bisulphite (sigma, usA) dissolved in 12,5ml of water, 
2,5ml of 1m hydroquinone (sigma, usA) and 3,5ml 2m naoH. 
All DnA samples were then gently homogenised and incubated at 70ºc for 3 hours with 450μl of the 
conversion mixture. Free sodium bisulphite must be removed to provide purified DnA. therefore, 900μl 
of Wizard DnA clean-up resin (promega, usA) was added to all samples. the resulting solution is placed 
into vertical columns and a vacuum is applied to draw the solution through. the bisulphite and hydro-
quinone excess are removed by washing the columns with 1,5ml of 80% isopropanol. the filter contai-
ning the DnA was transferred to a new eppendorf tube, and 45μl of ddH
2
o at 70ºc was added for DnA 
recovery. the tubes were then centrifuged (13000 rpm for 5 minutes) and the filter discarded. As the 
DnA must be kept in single-strand, 5μl of naoH was added. Finally, ammonium acetate and absolute 
ethanol were used to precipitate the converted DnA, which was further washed with 70% ethanol, dried 
at room temperature and finally eluted in ddH
2
o.
3.3. QuaNtItatIvE MEtHylatIoN-spECIfIC pCr
All samples were subjected to two reactions of amplification, one for the quantification of methylated 
MDR1 and the other for quantification of an internal reference gene (β-actin, which does not contain 
cpg islands) to normalize DnA input (costa et al., 2007b). the converted DnA, positive and negative 
controls, and commercial standards with serial dilutions of fully methylated DnA were amplified in the 
same run. these standards were used to construct a calibration curve in order to quantify the fully me-
thylated genes in the two reactions. pcr assays were performed in 96-well plate using a reaction volume 
of 20 μl. the final reaction mixture consisted of 600 nmol/l of each primer (invitrogen, carlsbad, cA); 
200 nmol/l probe (Applied biosystems, Foster city, cA); 1 unit of platinum taq polymerase (invitrogen, 
usA); 200 µmol/l concentration each of dAtp, dctp, dgtp, and dttp; 16.6 mmol/l ammonium sulfate; 67 
mmol/l trizma; 6.7 mmol/l magnesium chloride; 10 mmol/l mercaptoethanol; 0.1% Dmso, and 2 µl of 
bisulfite-converted genomic DnA. Amplification reactions were carried out in 50 cycles of denaturation 
at 95ºc for 15 seconds and annealing and extension at 60ºc for 60 seconds (Applied biosystems, usA). 
For each sample, the relative level of methylation in MDR1 promoter was obtained by dividing the value 
of methylated MDR1 by the respective value of β-actin, multiplying by 1000 for easier tabulation.
3.4. IMMuNoHIstoCHEMIstry
sections (3μm thick) from paraffin-embedded samples correspondent to the samples used for methyla-
tion analysis were obtained, deparaffinised in xylene and hydrated through a graded alcohol series. 
Antigen retrieval was accomplished by microwaving the specimens at 800W for 5 minutes with eDtA 
buffer. After cooling the slides, endogenous peroxidase activity was blocked by incubating the sections 
in hydrogen peroxide in 3% methanol for 30 minutes. the sections were treated with 5% normal horse 
129serum (vectastain, usA) in 1% pbs-bsA for 30 minutes to reduce background interference. the prima-
ry mouse monoclonal antibody (c494 clone, thermoscientific, uK) was applied in 1:50 dilution with 
1% pbs-bsA and left at 4ºc overnight. the secondary biotinylated horse antibody (vectastain, uK) at 
a dilution of 1:50 was added for 30 minutes. in order to enhance the immunohistochemical staining, 
the sections were incubated in avidin-biotin complexes for 30 minutes. then, 3,3’-diaminobenzidine 
(sigma, usA) was used for visualization and hematoxilin for counterstaining. Finally, after dehydration 
and diaphanization the slides were mounted in Entellan. imunohistochemistry results were categorized 
according to stain intensity into 2+ (expression similar to normal prostate tissue), 1+ (expression lower 
than normal prostate tissue), and 0 (no immunoexpression).
3.5. statIstICal aNalysIs
As the analyzed variables did not follow a normal distribution, nonparametric tests were used. in each 
group of samples, median and interquartile range (p25-p75) of MDR1 methylation levels were determi-
ned, and then compared through Kruskal-Wallis test or mann-Whitney u-test, depending on the num-
ber of categories in each group. the correlation between MDR1 promoter methylation levels and p-gp 
immunoexpression was assessed using Kruskall-Wallis test. statistical analysis was performed in Statistica 
for Windows, version 6.0 (statsoft, tulsa, oK, usA).
4. results
4.1. ClINICal aND patHologICal CHaraCtErIstICs
the clinical and pathological data of the patients is depicted in table 1. Although psA levels are higher in 
patients with pca (p=0,003), there is a striking overlap between psA values in pca and bpH patients. the 
median age of patients with bpH was significantly higher than patients with pca (p=0,00015).
4.2. MDR1 proMotEr MEtHylatIoN IN prostatIC tIssuE
According with a previous study including the same group of patients performed by baptista et al. 
(2006), the majority of the samples revealed methylation at MDR1 promoter region. Kruskall-Wallis sho-
wed significant differences in the distribution of methylation levels among all histological subtypes 
(p<0,00001), in particular between pca and Hgpin (p=0,00007), pca and bpH (p<0,00001), and Hgpin 
and bpH (p=0,00001).
4.3. p-gp IMMuNoExprEssIoN IN prostatIC tIssuEs
the majority of pca (89%) and Hgpin samples (79%) showed decreased p-gp expression (scores 0 and 
1+), whereas all bpH and mnp exhibited normal expression (2+, table 2). statistical analysis demonstrated 
significant hypermethylation differences between immunoexpression levels 0 and 2+, and between 1+ 
and 2+ (p<0,0001), showing that the higher MDR1 methylation levels are present in pca and Hgpin 
(Figure 2), whereas very low methylation is found in bpH and normal prostatic tissue. A representative 



























figure 2. correlation of MDR1 promoter methylation levels and p-gp 
immunoreactivity in prostate tissue samples. 
figure 3. immunoreactivity of p-gp in three distinct regions: (A) pca cells; 
(b) prostatic gland with Hgpin; and (c) normal prostatic gland.
5. Discussion and Conclusions
in the present study we evaluated how the promoter methylation and protein expression levels of MDR1 
vary in prostate carcinomas, high grade prostatic intraepithelial neoplasia, benign prostatic hyperplasia 
and morphologically normal prostate tissue. As reported by others, neoplastic prostate cells have shown 
lower p-gp expression (bhangal et al., 1999; Kawai et al. 2002). not only was this finding confirmed in 
our series, we could also demonstrate for the first time that higher promoter methylation levels of MDR1 
are significantly correlated with this loss of expression. our data therefore suggests that MDR1 hyperme-
131thylation is an effective mechanism of p-gp inactivation that may thus explain the frequent loss of MDR1 
expression in prostate cancer. 
it is interesting that the “multidrug resistance” role initially assigned to MDR1 (Ambudkar et al., 2003) 
represents a contradiction in the prostate carcinoma context. bearing in mind that hypermethylation 
generally silences the affected gene, the loss of p-gp expression may be interpreted as an unfavourable 
change for neoplastic cells. However, researchers on other neoplastic models showed that the expres-
sion of this glycoprotein in localised disease is higher than its expression in metastatic stages (scotlandi 
et al., 1999), indicating a connection between p-gp loss of expression and tumour progression.
As such, silencing MDR1 may be considered a therapeutic opportunity for treating patients with prosta-
te cancer. considering that curative treatment is not possible in locally advanced and/or metastatic pca, 
and that this tumor is resistant to conventional chemotherapy, the use of pharmacological agents usually 
detoxified by p-gp might be a functional alternative in pca treatment. biologically, the p-gp role is to drive 
xenobiotics (e.g., chemotherapeutic agents) out of cells and into urine and bile, thus removing them from 
the intracellular milieu/environment (Ambudkar et al., 2003). Hypothetically, reducing the expression of 
p-gp, mediated by MDR1 hypermethylation, will increase the efficacy of chemotherapeutic agents in trea-
ting prostate cancer. this assumption is quite important, since recent studies have shown that hormone-
refractory prostate cancer patients treated with taxanes have better survival rates (mackler et al., 2005).
in conclusion, our study has demonstrated a high prevalence of MDR1 promoter methylation in ma-
lignant prostate lesions, which could be significantly associated with the loss of p-gp expression in the 
same samples. Due to the role played by this protein in the removal of xenobiotics (e.g., taxanes, vinca 
alkaloids), the use of MDR1 epigenetic silencing as a therapeutic opportunity in the treatment of late 
stage prostate cancer is promising. However, further studies are needed to evaluate the role of MDR1 
hypermethylation in the treatment with taxanes in prostate carcinoma.
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